Product nameAnti-Hepatitis B Virus X antigen antibody [X36C]
See all Hepatitis B Virus X antigen primary antibodies
DescriptionMouse monoclonal [X36C] to Hepatitis B Virus X antigen
Tested applicationsSuitable for: IHC-P, ELISA, IP, WBmore details
Species reactivityReacts with: Hepatitis B virus
Recombinant full length protein corresponding to Hepatitis B Virus X antigen.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.05% Sodium azide
Concentration information loading...
Primary antibody notesHepatitis B Virus (HBV) infection induces a disease state which manifests itself in a variety of ways, characterized by the extent of liver damage, inflammation and viral persistence. HBV infection is also associated with a 100 fold increased risk of hepatocellular carcinoma and currently infects over 250 million people worldwide. HBV has a partially double stranded 3.2 kilobase DNA genome which contains four open reading frames. One of these encodes a 154 amino acid protein called the HBx protein. HBx has been shown to be a transcriptional transactivator of both viral and cellular promoters. Lacking a DNA binding domain and nuclear localization signal, HBx is believed to exert transcriptional activity through protein-protein interaction.
Our Abpromise guarantee covers the use of ab2741 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||Use at an assay dependent concentration.|
|ELISA||Use at an assay dependent concentration.|
|IP||Use at an assay dependent concentration.|
|WB||Use a concentration of 1 µg/ml.|
RelevanceHepatitis B virus X protein (HBx) is a 17 kD transcriptional coactivator that plays a significant role in the regulation of genes involved in inflammation and cell survival. It regulates many transcription factors including nuclear factor kappa B (NF-kappaB) and plays a key role in hepatocarcinogenesis. HBx facilitates the binding of cAMP response element binding protein (CREB) to its responsive element. HBx stabilizes the cellular coactivator ASC-2 through direct protein-protein interaction, affecting the regulation of genes actively transcribed in liver cancer cells. HBx transactivates both JNK and MAPK signal transduction pathways in association with the mobilization of cytosolic Ca2+. The communication between HBx and general transcription factor TFIIB is also one of the mechanisms which account for its transcriptional transactivation. HBx decreased the expression of PTEN a known tumor suppressor and a negative regulator of phosphatidylinositol 3'-kinase/AKT and HBx decreased the expression of PTEN in HBx-transfected cells. The etiology of hepatocellular carcinoma (HCC) is involved with hepatitis B virus (HBV) infection and HBx in particular plays a role in the development of HBV-related HCC. The persistence of HBx is important to the pathogenesis of early HCC and HBx expression in the liver during chronic HBV infection may be an important prognostic marker for the development of HCC.
- HBV X antigen antibody
- HBx antibody
- HBxAg antibody
All lanes : Anti-Hepatitis B Virus X antigen antibody [X36C] (ab2741) at 1/2000 dilution
Lane 1 : MIHA hepatocytes
Lane 2 : MIHA hepatocytes infected with lentivirus containing EGFP alone
Lane 3 : MIHA hepatocytes infected with lentivirus containing full length Hepatitis B Virus X antigen
Lanes 4-5 : MIHA hepatocytes infected with lentivirus containing truncated Hepatitis B Virus X antigen
This product has been referenced in:
- Zhong L et al. Reactive Oxygen Species-Mediated c-Jun NH2-Terminal Kinase Activation Contributes to Hepatitis B Virus X Protein-Induced Autophagy via Regulation of the Beclin-1/Bcl-2 Interaction. J Virol 91:N/A (2017). Read more (PubMed: 28515304) »
- Huang P et al. Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence. Clin Cancer Res 21:4420-30 (2015). Read more (PubMed: 26059188) »